Triple-negative breast cancer (TNBC) has long been one of the most difficult forms of breast cancer to treat. Unlike other breast cancer subtypes, TNBC lacks ...
Sarah Anderson, oncology strategy lead director, Novotech, discusses the growing prominence of triple-negative breast cancer ...
The efficacy of immunotherapy against triple-negative breast cancer (TNBC) heavily relies on intratumoral infiltration of ...
Pancreatic cancer is one of the deadliest of all cancers. Only 12% of men diagnosed with pancreatic cancer are alive five ...
Anixa Biosciences CEO Amit Kumar discusses the biotech’s plans for advancing a breast cancer vaccine in 2025. The cancer ...
Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune ...
The efficacy of immunotherapy against triple-negative breast cancer (TNBC) heavily relies on intratumoral infiltration of cytotoxic T lymphocytes ...
A study identifies promising compounds targeting PI3Kα for the treatment of triple-negative breast cancer, offering new ...
Nanovaccine achieved tumour inhibition rate of 89.3 per cent when tested on mice with aggressive form of the disease, study finds.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback